Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiken Biomedical CoTPE:7780 -0.90%23 Piotroski F-Score is 5 as of Aug. 20, 2026, which is at its 10-year median of 5.00. GuruFocus rates TPE:7780 with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 1,912 Consumer Packaged Goods companies, Daiken Biomedical Co ranks better than 51.1% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Daiken Biomedical Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Daiken Biomedical Co's Piotroski F-Score or its related term are showing as below:
TPE:7780'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 5 Max: 5
Current: 5
During the past 4 years, the highest Piotroski F-Score of Daiken Biomedical Co was 5. The lowest was 3. And the median was 5.
Daiken Biomedical Co (TPE:7780) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Daiken Biomedical Co Piotroski F-Score Related Terms
Daiken Biomedical Co Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Daiken Biomedical Co's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:7780 vs KHC, GIS: Piotroski F-Score Comparison
For the Packaged Foods subindustry, Daiken Biomedical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiken Biomedical Co Piotroski F-Score vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Daiken Biomedical Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Daiken Biomedical Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Jun26) TTM:
Last Year (Jun25) TTM:
Net Income was 69.423 + 124.644 + 104.355 + 126.539 = NT$425 Mil. Cash Flow from Operations was 34.63 + 123.048 + 79.485 + 25.437 = NT$263 Mil. Revenue was 449.325 + 656.111 + 463.842 + 616.343 = NT$2,186 Mil. Gross Profit was 287.935 + 401.285 + 278.74 + 382.544 = NT$1,351 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(1685.053 + 5653.314 + 5912.651 + 6115.807 + 6177.378) / 5 = NT$5108.8406 Mil. Total Assets at the begining of this year (Jun25) was NT$1,685 Mil. Long-Term Debt & Capital Lease Obligation was NT$14 Mil. Total Current Assets was NT$5,988 Mil. Total Current Liabilities was NT$1,261 Mil.
Net Income was 47.744 + 55.41 + 105.002 + 38.798 = NT$247 Mil.
Revenue was 294.044 + 543.915 + 334.774 + 454.879 = NT$1,628 Mil. Gross Profit was 191.203 + 344.785 + 223.021 + 293.488 = NT$1,052 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(1826.855 + 1719.708 + 1537.801 + 1664.134 + 1685.053) / 5 = NT$1686.7102 Mil. Total Assets at the begining of last year (Jun24) was NT$1,827 Mil. Long-Term Debt & Capital Lease Obligation was NT$0 Mil. Total Current Assets was NT$1,658 Mil. Total Current Liabilities was NT$577 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Daiken Biomedical Co's current Net Income (TTM) was 425.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Daiken Biomedical Co's return on assets of this year was 0.25219444. Daiken Biomedical Co's return on assets of last year was 0.13517986.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Daiken Biomedical Co's gearing of this year was 0.00265207. Daiken Biomedical Co's gearing of last year was 0.00018498.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Daiken Biomedical Co's current ratio of this year was 4.74923148. Daiken Biomedical Co's current ratio of last year was 2.87345856.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Daiken Biomedical Co's number of shares in issue this year was 790.869. Daiken Biomedical Co's number of shares in issue last year was 646.633.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Daiken Biomedical Co's gross margin of this year was 0.61790402. Daiken Biomedical Co's gross margin of last year was 0.64665104.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Daiken Biomedical Co's asset turnover of this year was 1.29706365. Daiken Biomedical Co's asset turnover of last year was 0.89093661.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
0
+
0
+
1
+
0
+
0
+
1
=
5
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Daiken Biomedical Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.
Daiken Biomedical Co (TPE:7780) has a Piotroski F-Score of 5 as of Aug. 20, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Daiken Biomedical Co and its competitors. This is near median its historical median of 5.00. Over the past decade, Daiken Biomedical Co's Piotroski F-Score has ranged from 3.00 to 5.00. According to the industry distribution chart, Daiken Biomedical Co ranks #935 out of 1912 companies in the Consumer Packaged Goods industry, placing it in the top 48.9%.
Is Daiken Biomedical Co's Piotroski F-Score too high?
Daiken Biomedical Co's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 5.00. The Consumer Packaged Goods industry median Piotroski F-Score is 5.00. Daiken Biomedical Co's value of 5 is 0% at this industry median. Based on the distribution chart, Daiken Biomedical Co ranks #935 out of 1912 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Daiken Biomedical Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Daiken Biomedical Co's Piotroski F-Score compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Daiken Biomedical Co ranks #935 out of 1912 companies for Piotroski F-Score. This puts Daiken Biomedical Co in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Daiken Biomedical Co's value of 5 is 0% at this benchmark. Historically, Daiken Biomedical Co's own Piotroski F-Score has ranged from 3.00 to 5.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Daiken Biomedical Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Consumer Packaged Goods company?
The median Piotroski F-Score among Consumer Packaged Goods companies is 5.00, based on 1,912 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiken Biomedical Co's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Daiken Biomedical Co and its competitors. For the Consumer Packaged Goods industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiken Biomedical Co's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Biomedical Co stock overvalued right now?
Daiken Biomedical Co (TPE:7780) has a current Piotroski F-Score of 5. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Consumer Packaged Goods industry median of 5.00. Daiken Biomedical Co's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Daiken Biomedical Co (TPE:7780), the current Piotroski F-Score is 5 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Daiken Biomedical Co Ltd is engaged in Research, development, and sales of health food. Its products include fish oil capsules, collagen powder, collagen drinks, natto capsules, and mint leaf capsules. The companies reportable operating segment consists solely of the e-commerce division.
23GF Score
Get the complete analysis for TPE:7780
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:7780 has been successfully added to your 
